Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤CUE-221 Phase 2 CSU study showed statistically significant, dose-responsive improvements in complete hive resolution.
- ➤CUE-221 4 mg/kg achieved 78% complete hive resolution versus 0% placebo in high-IgE patients.
- ➤CUE-401 entered Phase 1, with first-in-human dosing underway in the first cohort.
- ➤Third-quarter revenue fell to $0.1 million from $2.1 million year over year.
- ➤Third-quarter net loss widened to $50.0 million from $7.4 million; cash totaled $57.9 million.
Expert Statements
Pasha Sarraf, Chairman of the board of Cue Biopharma
“We are seeing exciting momentum across our portfolio”
Pasha Sarraf, Chairman of the board of Cue Biopharma
“We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.”
Pasha Sarraf, Chairman of the board of Cue Biopharma
“The additional clinical and pharmacological findings shared today from our Phase 2 CSU study reinforce CUE-221’s differentiated profile in CSU and provide a strong foundation to advance our food allergy program.”
Pasha Sarraf, Chairman of the board of Cue Biopharma
“In addition, commencement of dosing in our CUE-401 Phase 1 trial marks a significant milestone for Cue Biopharma as our first autoimmune therapeutic candidate enters the clinic.”
Shao-Lee Lin, President and chief executive officer of Cue Biopharma
“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies.”
Shao-Lee Lin, President and chief executive officer of Cue Biopharma
“In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience.”
Shao-Lee Lin, President and chief executive officer of Cue Biopharma
“CUE-401 is a potentially first-in-class dual-agonist, precision engineered by Cue scientists and designed to unlock the potential of TGF-β biology and restore immune tolerance.”
Shao-Lee Lin, President and chief executive officer of Cue Biopharma
“We believe this differentiated approach offers broad opportunities to address high unmet needs across autoimmune diseases.”
Shao-Lee Lin, President and chief executive officer of Cue Biopharma
“We look forward to sharing further progress as we advance our portfolio of therapies aimed at delivering durable, disease-modifying benefits across allergic and autoimmune diseases.”
* CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy
* CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone * Operating results reflect expenditures related to initiation of clinical development program expenses and non-cash charges BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported third quarter 2026 financial results as well as recent business highlights.
Get started
Create a free account to read the full story.
